Body Dysmorphic Disorder (BDD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Body Dysmorphic Disorder Clinical Trials Report Overview
Body dysmorphic disorder (BDD), also known as dysmorphophobia, is a severe psychiatric condition in which an individual spends a significant amount of time worrying about flaws in their own or another person’s appearance. These flaws are frequently overlooked by others. BDD can affect people of any age, but it is most common in teenagers and young adults. It affects both men and women.
The BDD marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products, and pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for body dysmorphic disorder (BDD). The report also analyzes the clinical and commercial landscapes of BDD as well as an assessment of key market players, and the future competitive environment.
Key Marketed Drugs | Fluoxetine, Opipramol hydrochloride, Escitalopram, Citalopram, Fluvoxamine, Sertraline, Paroxetine, Clomipramine, Buspirone, Clonazepam, and Pregabalin |
Key Countries | Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, the UK, and the US |
Key Sponsors in Terms of Clinical Trials | Swinburne University of Technology, St. Vincent’s Hospital Melbourne Pty Ltd, IRA Istituto Richerche Applicate SPA, Massachusetts General Hospital, Standford University, and New York State Psychiatric Institute |
Body Dysmorphic Disorder, Segmentation by Countries
The 16 major pharmaceutical markets include Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, the UK, and the US. Among all the countries India has the highest number of prevalent cases of BDD in 2023.
Body Dysmorphic Disorder, by Countries
For more insights on the prevalent cases of BDD, download a free report sample
Body Dysmorphic Disorder, Leading Marketed Drugs
Some of the leading BDD marketed drugs are Fluoxetine, Opipramol hydrochloride, Escitalopram, Citalopram, Fluvoxamine, Sertraline, Paroxetine, Clomipramine, Buspirone, Clonazepam, and Pregabalin. All SSRIs probably have equal effect for BDD, though the most preferred ones are fluoxetine, escitalopram, or sertraline. SSRI antidepressants allow the brain to use serotonin more effectively, not by producing more serotonin, but by making more serotonin available for longer periods.
Top Sponsors in Terms of Clinical Trials in the BDD Marketed and Pipeline Drugs Industry
Some of the top sponsors in the BDD marketed and pipeline drugs market in terms of clinical trials are Swinburne University of Technology, St. Vincent’s Hospital Melbourne Pty Ltd, IRA Istituto Richerche Applicate SPA, Massachusetts General Hospital, Standford University, and New York State Psychiatric Institute. Non-commercial sponsors dominated the clinical trials space in BDD over the past nine years, with Swinburne University of Technology sponsoring the highest number of clinical trials.
Body Dysmorphic Disorder, by Sponsors
To know more about the key sponsors, download a free report sample
Segments Covered in the Report
BDD Marketed and Pipeline Drugs, Country Outlook (No. of Prevalent Cases, 2023-2028)
- Australia
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Mexico
- Russia
- South Africa
- South Korea
- Spain
- The UK
- The US
Scope
GlobalData’s Body Dysmorphic Disorder (BDD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include –
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Pricing and Reimbursement Assessment
- Pipeline Assessment
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the BDD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BDD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which country has the highest number of prevalent cases of BDD in 2023?
India has the highest number of prevalent cases of BDD in 2023.
-
Which are the leading BDD marketed drugs?
Some of the leading BDD marketed drugs are Fluoxetine, Opipramol hydrochloride, Escitalopram, Citalopram, Fluvoxamine, Sertraline, Paroxetine, Clomipramine, Buspirone, Clonazepam, and Pregabalin.
-
Which are the key clinical trial sponsors in the BDD marketed and pipeline drugs industry?
Some of the top sponsors in the BDD marketed and pipeline drugs market in terms of clinical trials are Swinburne University of Technology, St. Vincent’s Hospital Melbourne Pty Ltd, IRA Istituto Richerche Applicate SPA, Massachusetts General Hospital, Standford University, and New York State Psychiatric Institute.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.